Uptake and binding of 3'-(3-cyano-4-morpholinyl)-3'-deaminoadriamycin and 3'-(4-morpholinyl)-3'-deaminoadriamycin in L5178Y lymphoblasts in vitro

Cancer Commun. 1990;2(1):7-12. doi: 10.3727/095535490820874803.

Abstract

3'-(3-Cyano-4-morpholinyl)-3'-deaminoadriamycin (CMA) and 3'-(4-morpholinyl)-3'-deaminoadriamycin (MA) are analogues of Adriamycin, with altered cytotoxic activity. CMA is 100- to 1500-fold more cytotoxic than Adriamycin and possesses unique DNA crosslinking activity. Intact MA does not crosslink DNA and has a cytotoxicity equivalent to Adriamycin, but it retains its activity in anthracycline-resistant cells. In this study, uptake and binding of [3H]CMA and [3H]MA in L5178Y lymphoblasts were examined. Both CMA and MA were rapidly taken up by cells at 37 degrees C and concentrated almost exclusively in the nucleus. All of the intracellular MA was TCA-soluble, but only 45% of this drug effluxed from the cells by 4 hr. More than 50% of CMA in the cells was TCA-insoluble, and approximately 40% effluxed from the cells by 4 hr through loss of the TCA-soluble fraction. CMA differed from other alkylating agents in that more than 97% of the bound drug was associated with DNA. The bound drug was partially lost from the DNA by a process that may have involved DNA repair.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / metabolism*
  • Binding Sites
  • Biological Transport
  • DNA, Neoplasm / metabolism
  • Doxorubicin / analogs & derivatives*
  • Doxorubicin / metabolism
  • Kinetics
  • Leukemia L5178 / metabolism*
  • Leukemia, Experimental / metabolism*
  • Mice
  • Neoplasm Proteins / metabolism
  • Protein Binding
  • RNA, Neoplasm / metabolism
  • Radioisotope Dilution Technique
  • Tritium
  • Tumor Cells, Cultured / metabolism*

Substances

  • Antibiotics, Antineoplastic
  • DNA, Neoplasm
  • Neoplasm Proteins
  • RNA, Neoplasm
  • Tritium
  • Doxorubicin
  • 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin